InflaRx N.V.

Report azionario NasdaqGS:IFRX

Capitalizzazione di mercato: US$349.1m

InflaRx Gestione

Criteri Gestione verificati 2/4

InflaRx Il CEO è Niels Riedemann, nominato in Jan2007, ha un mandato di 19.33 anni. possiede direttamente 0.73% delle azioni della società, per un valore di $ 2.53M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.8 anni e 7 anni.

Informazioni chiave

Niels Riedemann

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEOn/a
Mandato del CEO19.3yrs
Proprietà del CEO0.7%
Durata media del management3.8yrs
Durata media del Consiglio di amministrazione7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Articolo di analisi • Feb 06

Here's Why We're A Bit Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Nov 20

InflaRx: Gohibic Remains Niche, INF904 Underwhelms, Cash Burn Accelerates (Rating Downgrade)

Summary InflaRx faces worsening prospects as Gohibic remains niche, unprofitable, and unlikely to drive meaningful revenue growth. Attempts to expand vilobelimab into new indications failed, prompting a strategic pivot to the early-stage asset INF904. Early INF904 data in HS and CSU are underwhelming, with class safety concerns and past failures weighing on IFRX's outlook. With dwindling cash reserves and a high burn rate, IFRX is rated a clear 'Sell' due to excessive risks and uncertain turnaround. Read the full article on Seeking Alpha
Articolo di analisi • Jul 10

Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Jun 25

InflaRx (NASDAQ:IFRX) Will Have To Spend Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Articolo di analisi • Dec 23

We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Aug 17

InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Mar 28

We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Articolo di analisi • Nov 30

Can InflaRx (NASDAQ:IFRX) Afford To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 29

InflaRx seeks FDA emergency use nod for its treatment for critically ill COVID-19 patients

German clinical-stage biopharma InflaRx (NASDAQ:IFRX) on Thursday said it had submitted an emergency use approval request to the U.S. FDA for its monoclonal antibody vilobelimab to treat critically ill COVID-19 patients. The company also said it was granted a fast track designation from the U.S. drug regulator for vilobelimab. IFRX stock +5.6% to $2.63 in early trading. The submission for the emergency use nod and the fast track clearance was based on the results of phase 3 studies conducted in invasively mechanically ventilated, critically ill COVID patients, IFRX said in a statement. The FDA's Fast Track approval is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The submission from InflaRx (IFRX) comes at a time when COVID cases in the U.S. are expected to rise in the fall and winter season.
Seeking Alpha • Aug 05

InflaRx reports Q2 results

InflaRx press release (NASDAQ:IFRX): Q2 GAAP EPS of €0.01. On June 30, 2022, the Company’s total funds available were approximately €91.8 million, composed of cash and cash equivalents of €15.4 million and marketable securities of €76.4 million. These funds are expected to finance operations until year-end 2024.
Seeking Alpha • Jul 26

InflaRx stock rises 13% on plans to file EUA for COVID drug in US for critically ill patients

InflaRx (NASDAQ:IFRX) stock rose ~13% on July 26 after its CEO Niels Riedemann said the company plans to submit a request for an emergency use authorization (EUA) of its COVID-19 drug vilobelimab in the U.S. by the end of Q3. The Germany company said it had encouraging interactions with the U.S. Food and Drug Administration (FDA) at a recent Type B meeting which was held to discuss a potential EUA filing and the development of monoclonal antibody vilobelimab for critically ill invasively mechanically ventilated patients with COVID-19. InflaRx noted that it discussed in detail a completed phase 3 part of the PANAMO study in invasively mechanically ventilated, critically ill patients with COVID-19. In March, the company reported data from the phase 3 trial in which vilobelimab did not show statistical significance in reducing risk of death in mechanically ventilated patients with COVID-19. "Our constructive interactions with the FDA and the helpful guidance they provided have encouraged us to move forward with applying for EUA for vilobelimab in critically ill COVID-19 patients," said InflaRx Founder and CEO Riedemann.
Articolo di analisi • Jul 16

Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Jul 06

InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder

The U.S. Food and Drug Administration (FDA) granted fast track designation to InflaRx's (NASDAQ:IFRX) vilobelimab to treat ulcerative pyoderma gangrenosum (PG). PG is a rare disorder which causes large, painful ulcers to develop on the skin, often on the legs. The company had had submitted a request for a fast track designation after positive data in a phase 2a trial in PG, Germany-based InflaRx said in a July 6 press release. Vilobelimab has already received orphan drug status for PG in the U.S. and EU. IFRX +14.08% to $1.62 premarket July 6
Seeking Alpha • Jun 29

InflaRx granted FDA Type B meeting to discuss submissions for COVID therapy

German biotech InflaRx N.V. (NASDAQ:IFRX) announced on Wednesday that the FDA agreed to a Type B meeting as the company seeks emergency use authorization for its COVID-19 therapy, vilobelimab  InflaRx (IFRX) has engaged the agency to discuss the future regulatory path for vilobelimab in COVID-19 after its multi-national PANAMO study for patients with the severe form of the disease generated favorable Phase 3 results early this year. The FDA has scheduled a Type B meeting for early Q3 to provide guidance on a potential emergency use authorization submission. Meanwhile, the discussions with the European Medicines Agency (EMA) are currently underway, targeting a regulatory submission for the same indication. Updating on the development of vilobelimab for the rare skin disorder pyoderma gangrenosum, InflaRx (IFRX) said that the company is now finalizing the design for a Phase III trial. That was after an end-of-phase II meeting, in which the FDA supported a randomized, controlled late-stage study and offered to review the study protocol. Read more on the topline data from the PANAMO study.
Articolo di analisi • Apr 01

Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Dec 29

Our First Look At InflaRx

Today, we shine the spotlight on InflaRx, a small biotech concern based in Germany. The stock is deep in 'Busted IPO' territory even as the company has seen an increasing amount of news flow around it in recent months. A full investment analysis follows in the paragraphs below.

AMMINISTRATORE DELEGATO

Niels Riedemann (52 yo)

19.3yrs
Mandato

Prof. Dr. Niels C. Riedemann, M.D. is Chief Executive Officer of InflaRx N.V. since 2007 and serves as its Executive Director. He founded InflaRx N.V. in 2007 as InflaRx GmbH. He spent several years in bas...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Niels Riedemann
Co-Founder19.3yrsNessun dato0.73%
$ 2.5m
Renfeng Guo
Co-Founder19.3yrsNessun dato1.2%
$ 4.2m
Thomas Taapken
Chief Financial Officer5.6yrsNessun dato0.0024%
$ 8.3k
Derval O'Carroll
Senior VP and Global Head of Regulatory Affairs & Compliance3.1yrsNessun dato0%
$ 0
Camilla Chong
Chief Medical Officer2.8yrsNessun dato0%
$ 0
Jan Medina
Head of Investor Relations & VP2.3yrsNessun datoNessun dato
Christian Schmid
VP and Head of Legal Affairs & General Counselno dataNessun datoNessun dato
Maria Habel
VP, Head of Preclinical R&D and QC13.3yrsNessun datoNessun dato
Kofi Boaten
VP and Head of Supply Quality & Clinical Trial Suppliesno dataNessun datoNessun dato
Peter Hurt
Senior Director and Head of Drug Safety & Pharmacovigilianceno dataNessun datoNessun dato
Daniel Vetter
Senior Director & Head of IT3.8yrsNessun datoNessun dato
Igor Orshanskiy
Senior Director & Head of Business Development2.5yrsNessun datoNessun dato
3.8yrs
Durata media
57yo
Età media

Gestione esperta: Il team dirigenziale di IFRX è considerato esperto (durata media dell'incarico 3.8 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Niels Riedemann
Co-Founderno dataNessun dato0.73%
$ 2.5m
Renfeng Guo
Co-Founderno dataNessun dato1.2%
$ 4.2m
Nicolas Fulpius
Independent Chairman of the Board19.3yrsNessun dato0.33%
$ 1.2m
K. Reinhart
Member of Scientific Advisory Boardno dataNessun datoNessun dato
P. Ward
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Richard Brudnick
Independent Non-Executive Director7yrsNessun dato0.034%
$ 118.5k
Hege Hellstrom
Non-Executive Director3.1yrsNessun dato0%
$ 0
Mark Kubler
Independent Non-Executive Director11.3yrsNessun dato0.65%
$ 2.3m
Anthony Gibney
Independent Non-Executive Director5yrsNessun dato0.0068%
$ 23.7k
7.0yrs
Durata media
54yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di IFRX sono considerati esperti (durata media dell'incarico 7 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/20 05:13
Prezzo dell'azione a fine giornata2026/05/20 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

InflaRx N.V. è coperta da 16 analisti. 6 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Madhu KumarBaird
Mayur SomaiyaBMO Capital Markets Equity Research
Madhu KumarB. Riley Securities, Inc.